文献速递血栓与止血

静脉血栓栓塞症诊断与治疗基础

Basics of diagnosis and treatment of venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2025-02-10

本文综述静脉血栓栓塞症(VTE)的诊断与治疗基础框架,涵盖深静脉血栓与肺栓塞。诊断采用临床概率评分联合D-二聚体识别低概率患者以安全排除诊断;确诊后以抗凝为主要治疗,高危患者可受益于溶栓和/或介入再灌注治疗,直接口服抗凝药简化了多数患者治疗。

要点

  • 临床概率评分联合D-二聚体可用于识别低概率VTE患者,无需影像学即可安全排除诊断。
  • 确诊VTE后抗凝是主要治疗,高危特征患者可能受益于溶栓和/或介入再灌注治疗。
  • 初始抗凝3至6个月后,具有主要短暂诱发因素者可安全停用抗凝。

核心结论

  • 本综述提供深静脉血栓和肺栓塞诊断方法、确诊后风险分层及管理的基本概述与框架。

研究设计与样本

  • 综述,提供VTE诊断、风险分层与管理的基本概述与框架。

主要发现

  • VTE包括深静脉血栓和肺栓塞,常见且与显著发病率和死亡率相关。
  • VTE症状和体征非特异性,成熟的整合诊断策略联合临床概率评分和D-二聚体可用于识别低概率患者,无需影像学即可安全排除诊断。
  • 确诊VTE患者中抗凝是主要治疗,但就诊时具有高危特征的患者可能受益于溶栓和/或介入等先进再灌注治疗以降低早期死亡率和/或长期发病率。
  • 直接口服抗凝药的出现极大简化了多数VTE患者的治疗,低分子量肝素和维生素K拮抗剂在特定患者群体中仍有持续作用。
  • 初始抗凝3至6个月后,具有主要短暂诱发因素者可安全停用抗凝。

关键数值与推荐

  • 初始抗凝持续3至6个月后,具有主要短暂诱发因素者可安全停用抗凝。
  • 长期抗凝决策的核心是平衡复发性VTE风险与出血风险,患者应参与共同决策。

临床怎么用

  • 诊断方面采用临床概率评分联合D-二聚体的整合策略识别低概率VTE患者,无需影像学即可安全排除诊断。
  • 确诊VTE后以抗凝为主要治疗,高危特征患者可能受益于溶栓和/或介入再灌注治疗。
  • 多数患者可使用直接口服抗凝药,特定患者群体中低分子量肝素和维生素K拮抗剂仍有作用。
  • 初始抗凝3至6个月后,具有主要短暂诱发因素者可安全停用抗凝;长期抗凝需平衡复发与出血风险并纳入共同决策。
  • 应评估和识别血栓后综合征、肺栓塞后综合征等长期并发症,以及慢性血栓栓塞性肺动脉高压。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism (PE), is common and associated with significant morbidity and mortality. The symptoms and signs of VTE are nonspecific. Well-established integrated diagnostic strategies combining clinical probability scores and D-dimer are used to identify patients with a low probability of VTE, where the diagnosis can be safely excluded without imaging. In patients with confirmed VTE, anticoagulation is the mainstay of treatment. However, patients with high-risk features at presentation may benefit from advanced reperfusion therapies such as thrombolysis and/or interventional approaches to reduce early mortality and/or long-term morbidity. The advent of direct oral anticoagulants has greatly simplified the treatment of VTE for most patients, with a persisting role for low molecular weight heparin and vitamin K antagonists in select patient groups. Following an initial 3 to 6 months of anticoagulation, those with major transient provoking factors can safely discontinue anticoagulation. Balancing the risk of recurrent VTE and bleeding risk is central to decisions regarding long-term anticoagulation, and patients should be included in shared decision-making. Assessment and recognition of common long-term complications such as postthrombotic syndrome and post-PE syndrome are also essential, given they are associated with significant adverse impact on long-term quality of life, with a significant risk of mortality associated with the less frequent complication of chronic thromboembolic pulmonary hypertension. This review provides a basic overview and framework for the diagnostic approach to deep vein thrombosis and PE, risk stratification of confirmed diagnoses, and management.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Cox C, Roberts LN. Basics of diagnosis and treatment of venous thromboembolism. J Thromb Haemost. 2025. PMID: 39938684. doi:10.1016/j.jtha.2025.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。